Background

Accomplished corporate development, M&A, intellectual property management and strategy professional with proven history guiding all phases of business valuation, market analysis, product assessment, and financial modeling. Track record of success leading teams. Excellent communicator and innovative problem solver, with strong team leadership capabilities.

Job experience

• December 2023 - present
  Business Development and Strategy
  GAR CONSULTING
  

  Provide business development and strategic advice to startups. Advised site management organization startup of potential strategic targets. Provided market research and market sizing for clinical research organization market to startup company.

• January 2020 - November 2023
  Global Director of Business Development & Strategy
  SIRTEX MEDICAL
  

  Lead all aspects of the corporate development process. Responsible for building and maintaining M&A deal pipeline aligned with the corporate strategy. Identifies acquisition opportunities, evaluates targets based on strategic and financial criteria and assesses overall organizational fit. Executes strategies to identify, assess, and pursue new business opportunities. Prepares and delivers presentations to the Senior Leadership Team, M&A Committee, and the Board of Directors. Directs due diligence, financial modeling, transaction analysis, valuation, deal structuring, negotiation and deal closing. Builds collaborative relationships of internal constituents and external parties including financial advisors (such as PE firms and investment banks).
  Selected Achievements:
  · Led the $5 million strategic equity acquisition transaction of BlackSwan Vascular, Inc. Conducted strategic landscaping, financial and business case modeling. Co-chaired the negotiations. Led the cross-functional due diligence team.
  · Completed the $25 million acquisition of BlackSwan Vascular, Inc. Post-Directed the post-acquisition integration team
  · Led the establishment of a projected multi-million dollar revenues R&D collaboration and exclusive worldwide distribution agreement with Magle Group
  · Acquired the U.S. rights to co-promote OncoSec’s lead clinical phase product in development
  · Conducted strategic analysis, financial modeling, and due diligence resulting in the $5 million investment in Nanospectra
  · Created strategic plan, competitive landscape, and potential target list for expansion into radiopharmaceuticals
  · Developed five-year strategic plan to grow by 5 time revenues with inorganic growth accounting for 70% of the growth

• May 2015 - January 2020
  Director of Evaluation, Business Development and Strategy
  AMAG PHARMACEUTICALS
  

  Lead all aspects for business development opportunities working collaboratively with the Chief Business Officer and Chief Executive Officer. Handle a wide range of projects and engages with prospective partners and lead cross-functional teams to evaluate opportunities. Conduct forecasting, financial modeling and lead due diligence teams comprised of internal and external resources. Establish networks to ensure early identification and capture of relevant opportunities.
  Selected Achievements:
  · Led strategic reviews and boil-the-ocean exercises for our hematology/oncology business division resulting in the following:
   Converted royalty bearing license to fully paid-up royalty free license for MuGard and ProctiGard. Conducted the divestiture of these products for more than 5 times current revenues
   Led the US$410 million acquisition of Perosphere Pharmaceuticals, including its Phase 2 clinical trial drug
  · Led the US$700 million acquisition of Cord Blood Registry including leading the diligence team and valuation activities
  · Scouted Palatin Technologies’ product and held initial discussion and initial due diligence resulting in a worldwide license

• July 2006 - May 2015
  Strategic Planning Project Lead
  BAYER HEALTHCARE, LLC
  

  Business Development & Licensing – Asia Pacific Region for Bayer Healthcare, Beijing, China 11/2014-02/2015
  Conduct development and licensing activities, including strategic partnership evaluations for the Asia Pacific region. Prepare and present business cases and recommendations for executive team and corporate stakeholders.
  Strategic Planning (StraCo) Project Lead/Senior Manager, Strategic Business Unit Controller 01/2012-05/2015
  Manage a staff creating the Medical Care Division’s 5-year strategic plan for two business units: Radiology & Interventional (R&I) and Diabetes Care (DC). Led projects with impact on Medical Care strategy; conducted comprehensive analyses, derived options and prepared Senior Management Teams (SMT) presentations that led to high-impact decisions. Manage a staff providing operational oversight and budget support to the R&I Strategic Business Unit.
  Selected Achievements:
  · Prepared and consolidated the five-year strategic planning by collecting and analyzing plans and economic data from various sources and recommended strategic business plans
  · Ensured the budget planning process and monthly reporting for the Strategic Business Unit’s 20 million Euros cost center by coordinating with the regional, country, and functional team resulting in the best year-end budget results in the division
  Manager, Business Planning and Analysis 01/2011-01/2012
  Manage a staff providing financial leadership for R&D projects, brand and portfolio analysis and project management budgets. Provide technical leadership to divisional management in understanding of brand profitability and research and development projects. Create strategies related to competitive positioning. Appointed member of the divisional Patent Management Committee, providing strategic management of divisional patent portfolio. Lead cross-functional teams in creating strategies for product innovations and appropriations for major capital investments, mergers & acquisitions and divestitures.
  Selected Achievements:
  · Conducted financial analysis for next generation worldwide product launch strategies that replaced current product base
  · Monitored financial evolution of current brands and new product introductions
  · Developed the 5-year divisional strategic plan (StraCo) and led the presentation to Bayer AG’s Corporate Development team including the brand profitability strategies
  · Recommended and implemented operational improvements to research and development stage gate process
  Manager, Global Business Development & Strategic Initiatives 07/2006 – 12/2010
  Lead aspects of M&A, strategic alliances, IP and out-licensing activities, including valuation, financial/accounting due diligence, and completion of in-depth operational, legal, tax, organizational, and systems reviews. Prepare and present business cases and recommendations for executive team and corporate stakeholders. Conduct deal triage for emerging technologies, products, and portfolio mix in medical device, and e-health arenas. Craft and implement 5-year divisional strategic plan. Prepare responses to Request for Proposals for strategic alliances. Develop IP strategy for short- and long-term success. Conduct white space analysis of the state-of-the-art technologies and overall market to determine potential acquisitions, partnerships, and internal projects
  Selected Achievements:
  · Launched IP monetization program for Bayer’s Diabetes Care Division (BDC) in 2009, secured landmark first out-licensing agreement along with first ever sale of a BDC trademark
  · Coordinated acquisition of iSense to gain foothold into continuous glucose monitoring market, with projected 2+-year improvement in initial product launch and having projected revenues of $ 200 million in the first three years
  · Captured 2 strategic alliances and an additional corporate acquisition with expected combined revenues of $1B+

Education

• University of Michigan, Ross School of Business
  M.B.A.
  

  - present

  Finance & Strategy
• Rensselaer Polytechnic Institute
  M.Eng.
  

  - present

  Nuclear Engineering
• Rensselaer Polytechnic Institute
  B.S.
  

  - present

  Nuclear Engineering